All news
Kick-Off Event for the SmartCARE Project
19 April 2023On 28 March, key collaborators from the smartCARE consortium gathered in Brussels to share ideas and perspectives. Haidar Akl, a member of our scie...
A Wind of Change in the EU’s Pharmaceutical Landscape
19 April 2023The challenge that the European Commission set itself up for in revising the EU’s Pharmaceutical Legislation (namely Directive 2001/83/EC1 an...
Colores Finland Shares Effort to Support People Living with Lynch Syndrome
18 April 2023Lynch Syndrome impacts several areas of life. Patients can benefit from collaboration with specialists across many fields, especially input from Ly...
EuropaColon Poland Received “Swallow of Hope Award”
18 April 2023Congratulations to our member organisation EuropaColon Poland Foundation for Patients, on receiving the “Swallow of Hope”, a national Polish aw...
TOGAS: Towards Gastric Cancer Screening Implementation in the European Union
17 April 2023On 30 – 31 March, DiCE participated in the kick-off meeting of the TOGAS project held in Riga, Latvia. TOGAS, which stands for TOwards GAstri...
Liver Cancer Index – The Mapping Survey Is Available Online
17 April 2023The survey was created to map the liver cancer treatment landscape across the EU and is now available online and disseminated among several relevan...
EuropaColon Slovenia Celebrates Its 15th Anniversary
17 April 2023This March EuropaColon Slovenia rang in its 15th anniversary as a patient association! EC Slovenia was an original member of EuropaColon, the Europ...
Primary Findings From The GLOW Study Signals Positive Momentum In The Development Of Novel Therapeutic Options For Patients With HER2-Negative Locally Advanced Unresectable Or Metastatic Gastric & GEJ Cancers
20 March 2023At the end of 2022, leaders of the Phase 3 clinical trial GLOW shared their positive primary findings. GLOW (NCT03653507) is a global, multicenter,...
Health Is Local – DiCE Members Organise National Policy Events
20 March 2023At DiCE, we aim to cover both European and national aspects of policymaking. That is why this year, we will be supporting DiCE Member Organisations...
Trastuzumab Deruxtecan Meets Objective Response Rate Endpoint in Several Types of HER2-expressing Advanced Solid Tumours
20 March 2023Positive topline results of the ongoing DESTINY-PanTumour02 Phase II trial (NCT04482309) showed that treatment with trastuzumab deruxtecan met the...
